![](https://library.celltelligence.com/wp-content/uploads/2020/10/Allogene-Announcement.png)
$0
First Patient Dosed in Allogene’s ALLO-715 + Nirogacestat Cohort in the Ph1 UNIVERSAL Trial
On Monday, April 12, Allogene and SpringWorks announced (press release) that the first patient has been dosed with ALLO-715 (BCMA CAR-T) + nirogacestat (GSI) in the Ph1 UNIVERSAL trial (r/r MM). Below, Celltelligence provides insights into Allogene’s and key competitor Precision Biosciences’s clinical progress combining a GSI with their lead BCMA CAR-T assets, while discussing other strategies currently under evaluation to improve BCMA-targeting CAR-T efficacy.